Biocompatible, Multiresponsive Nanogel Composites for Codelivery of Antiangiogenic and Chemotherapeutic Agents

Single therapy approaches are usually insufficient to treat certain diseases, due to genetic differences between patients or disease resistance. Therefore, such approaches are gradually replaced by combination therapies comprising two or more drugs. In oncology, these include BRAF inhibitors and cytotoxic, antiangiogenic, or immunomodulatory agents, among others. We propose herein the use of multiresponsive nanogel composites for the codelivery of a DNA intercalator (doxorubicin) and an antiangiogenic and immunomodulatory agent (pomalidomide). We introduce a surfactant-free synthetic protocol to decorate biocompatible poly(ethylene glycol)methacrylate nanogels (PEGMA) with evenly distributed gold nanoparticles and explore their ability to deliver drugs upon stimulation by various triggers such as heat, light, and reducing agents present in the intracellular environment. We further demonstrate that an additional polymer coating on the nanogel surface can decrease uncontrolled drug leakage and modulate cell...